Strategies and assays for the assessment of unwanted immunogenicity

Journal of Immunotoxicology

Volumn 3, Issue 3, 2006, Pages 115-121

  Wadhwa, Meenu ^a   Thorpe, Robin ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Immunoassays; Immunogenicity; Neutralization assays; Strategy; Validation

Indexed keywords

ANTIBODY DETECTION; ASSAY; BIOTECHNOLOGY; CONFERENCE PAPER; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; METHODOLOGY; MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOPRECIPITATION; RISK ASSESSMENT; SURFACE PLASMON RESONANCE; VALIDATION PROCESS;

EID: 33747584697     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910600845534     Document Type: Conference Paper

References (26)

1. Antonelli, G., Currenti, M., Turriziani, O., and Dianzani, F. 1991. Neutralizing antibodies to interferon-alpha: Relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 163:882-885.
2. Baert, F., Noman, M., Vermiere, S., Assche, G. V., D'Haens, G., Carbonez, A., and Rutgeerts, P. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348:601-608.
3. Bertolotto, A. 2004. Neutralizing antibodies to interferon beta: Implications for the management of multiple sclerosis. Curr. Opin. Neurol. 17:241-246.
4. Bertolotto, A., Deisenhammer, F., Gallo, P., and Solberg Sorensen, P. 2004. Immunogenicity of interferon beta: Differences among products. J. Neurol. 251 Suppl 2:II15-II24.
5. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J. J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., and Mayeux, P. 2002. Pure red cell aplasia and anti-erythropoietin antibodies against human erythropoietin in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469-475.
6. CPMP (Committee for Proprietary Medicinal Products). 2004. Guideline on Comparability of Medicinal Products Containing Biotechnology-derived Proteins as Active Substance. Non-clinical and Clinical Issues. EMEA/CPMP/3097/02.
7. Francis, G. S., Rice, G. P., and Alsop, J. C. 2005. PRISMS Study Group. Interferon beta-1a in MS: Results following development of neutralizing antibodies in PRISMS. Neurology 65:48-55.
8. Hjelm Skog, A. L., Wadhwa, M., Hassan, M., Gharizadeh, B., Bird, C., Ragnhammar, P., Thorpe, R., and Mellstedt, H. 2001. Alteration of IL-2 pharmacokinetics and function by IL-2 antibodies induced following treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, GM-CSF, and IL-2. Clin. Cancer Res. 7:1163-1170.
9. International Conference on Harmonization. 1997. Guidance for Industry. S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Available at 〈http://www.fda.gov/cder/guidance/1859fnl.pdf〉.
10. Kitamura, T., Tange, T., Terasawa, T., Chiba, A., Kuwaki, T., Miyagawa, K., Piao, Y. F., Miyazono, K., Urabe, A., and Takaku, F. 1989. Establishment and characterization of a unique human cell line that proliferates dependently on GMCSF, IL-3, or erythropoietin. J. Cell. Physiol. 140:323-334.
11. Koren, E., Zuckerman, L. A., and Mire-Sluis, A. R. 2002. Immune responses to therapeutic proteins in humans-Clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349-360.
12. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., and Kuter, D. J. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241-3248.
13. McKay, F., Schibeci, S., Heard, R., Stewart, G., and Booth, D. 2006. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: A comparison of three methods in a large Australasian cohort. J. Immunol. Meth. 310:20-29.
14. Mire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S. J., Taniguchi, G., Wierda, D., and Zuckerman, L. A. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Meth. 289:1-16.
15. Patton, A., Mullenix, M. C., Swanson, S. J., and Koren, E. 2005. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Meth. 304:189-195.
16. Porter, S. 2001. Human immune response to recombinant human proteins. J. Pharm. Sci 90:1-11.
17. Rosenberg, M., Kingma, W., Fitzpatrick, M. A., and Richards, S. M. 1999. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93:2081-2088.
18. Saint-Remy, J. M. 2002. Immunology of factor VIII inhibitors. Semin Thromb. Hemost. 28:265-268.
19. Stein, K. E. 2002. Immunogenicity: Concepts/issues/concerns. Devel. Biol. 109:15-23.
20. Steis, R., Smith, J. W., Urba, W. J., Clark, J. W., Itri, L. M., Evans, L. M., Schoenberger, C., and Longo, D. 1988. Resistance to recombinant interferon alpha-2a in hairy-cell leukaemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318:1409-1413.
21. Swanson, S. J., Mytych, D., and Ferbas, J. 2002. Use of biosensors to monitor the immune response. Devel. Biol. 109:71-78.
22. Thorpe, R., and Swanson, S. J. 2005. Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin. Diag. Lab. Immunol. 12:28-39.
23. Wadhwa, M., Bird, C., Fagerberg, J., Gaines-Das, R., Ragnhammar, P., Mellstedt, H., and Thorpe, R. 1996. Production of neutralizing GM-CSF antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol. 104:351-358.
24. Wadhwa, M., Skog, A. H., Bird, C., Ragnhammar, P., Lilljefors, M., Gaines-Das, R., Mellstedt, H., and Thorpe, R. 1999. Immunogenicity of granulocyte-macrophage colony stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin. Cancer Res. 5:1353-1361.
25. Wadhwa, M., Bird, C., Dilger, P., Gaines-Das, R., and Thorpe, R. 2003. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Meth. 278:1-17.
26. Wei, X., Swanson, S. J., and Gupta, S. 2004. Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J. Immunol. Meth. 293:115-126.